Citations

Showing 10 of 108081 citations.

Atrial Appendage Aneurysms: Natural History and Outcomes
Penfold, Michael , Connolly, Heidi M. , Dearani, Joseph A. , Miranda, William R. , Asirvatham, Samuel J. , Killu, Ammar M. , Stephens, Elizabeth H. , Dearani, Joseph A. , Penfold, Michael P , Asirvatham, Samuel J , Haq, Ikram-Ul, Schaff, Hartzell V. , Arghami, Arman

Mayo Clinic

World Journal for Pediatric and Congenital Heart Surgery | March 27, 2023 | Volume: 14 | Issue: 4 | Pages: 474-480

10.1177/21501351231162909 | PMID 36972504 Get It

Background Left (LAAA) and right atrial appendage aneurysms (RAAA) are rare entities, and their natural history, management, and long-term outcomes are not well studied. Methods This retrospective review includes all patients from 2000 to 2021 with atrial appendage aneurysms at our institution identified using an electronic search tool. LAAA and RAAA were confirmed using multimodality imaging and intraoperative findings. Results We identified 13 (87%) patients with LAAA and 2 (13%) with RAAA. At diagnosis, 11 (73%) were female, mean age was 51.4 ± 18.8 years, and ejection fraction 56.5 ± 13.1%. Three (20%) patients had congenital heart disease including 2 (13%) with atrioventricular septal defects and 1 (7%) with congenitally corrected transposition. LAAA/RAAA was diagnosed due to new-onset atrial fibrillation (AF) in 6 (40%) patients and embolic stroke in 2 (13%). Ten patients had preexisting AF diagnosed 2.9 ± 1.4 years earlier at a mean age of 50.2 ± 15.5 years. Thrombus within the aneurysm was identified in 2 (15%) LAAA patients. All patients were on anticoagulation and follow-up of the cohort from diagnosis was 7.1 ± 6.2 years. Eleven (73%) patients were surgically managed with 7 (64%) lesions excised, 1 (9%) stapled, and 3 (27%) ligated. Postoperative complications occurred in 2 (18%) patients with 1 (7%) developing tricuspid regurgitation and another with pericardial effusion and tamponade. Conclusions Atrial appendage aneurysm is a rare disease and nearly half of patients present with AF. Surgical treatment with concomitant AF ablation is a reasonable and safe management option.
Paraspinal Sarcopenia is Associated With Worse Patient-Reported Outcomes Following Laminoplasty for Degenerative Cervical Myelopathy
Pinter, Zachariah W. , Reed, Ryder, Townsley, Sarah E., Mikula, Anthony L. , Lakomkin, Nikita , Kazarian, Erick R., Michalopoulos, Giorgos D. , Freedman, Brett A. , Currier, Bradford L. , Elder, Benjamin D. , Bydon, Mohamad , Fogelson, Jeremy L. , Sebastian, Arjun S. , Kazarian, Erick, Fogelson, Jeremy, Michalopoulos, Giorgos , Nassr, Ahmad

Mayo Clinic

Spine | March 27, 2023 | Volume: 48 | Issue: 11 | Pages: 772-781

10.1097/brs.0000000000004650 | PMID 36972148 Get It

Study Design. Retrospective cohort study. Objective. The present study is the first to assess the impact of paraspinal sarcopenia on patient-reported outcome measures (PROMs) following cervical laminoplasty. Background. While the impact of sarcopenia on PROMs following lumbar spine surgery is well-established, the impact of sarcopenia on PROMs following laminoplasty has not been investigated. Methods. We performed a retrospective review of patients undergoing laminoplasty from C4-6 at a single institution between 2010 and 2021. Two independent reviewers utilized axial cuts of T2-weighted magnetic resonance imaging sequences to assess fatty infiltration of the bilateral transversospinales muscle group at the C5-6 level and classify patients according to the Fuchs Modification of the Goutalier grading system. PROMs were then compared between subgroups. Results. We identified 114 patients for inclusion in this study, including 35 patients with mild sarcopenia, 49 patients with moderate sarcopenia, and 30 patients with severe sarcopenia. There were no differences in preoperative PROMs between subgroups. Mean postoperative neck disability index scores were lower in the mild and moderate sarcopenia subgroups (6.2 and 9.1, respectively) than in the severe sarcopenia subgroup (12.9, P=0.01). Patients with mild sarcopenia were nearly twice as likely to achieve minimal clinically important difference (88.6 vs. 53.5%; P<0.001) and six times as likely to achieve SCB (82.9 vs. 13.3%; P=0.006) compared with patients with severe sarcopenia. A higher percentage of patients with severe sarcopenia reported postoperative worsening of their neck disability index (13 patients, 43.3%; P=0.002) and Visual Analog Scale Arm scores (10 patients, 33.3%; P=0.03). Conclusion. Patients with severe paraspinal sarcopenia demonstrate less improvement in neck disability and pain postoperatively and are more likely to report worsening PROMs following laminoplasty. Level of Evidence. 3
Comparison Between the Supracerebellar Infratentorial and Precuneal Interhemispheric, Transtentorial Approaches to the Cerebellomesencephalic Fissure: An Anatomoradiological Study and Illustrative Cases
Alexander, A. Yohan , Leonel, Luciano, Peris‐Celda, Maria , Alexander, A Yohan , Agosti, Edoardo , Lanzino, Giuseppe

Mayo Clinic

Operative Neurosurgery | March 27, 2023 | Volume: 25 | Issue: 1 | Pages: e6-e14

10.1227/ons.0000000000000684 | PMID 36972426 Get It

BACKGROUND: The dorsal brainstem and cerebellomesencephalic fissure are challenging surgical targets. To afford a preferentially craniocaudal trajectory to this region, the precuneal interhemispheric transtentorial approach (PCIT) has been proposed. OBJECTIVE: To didactically describe and compare exposures and anatomic indications of the supracerebellar infratentorial approach (SCIT) and PCIT to the cerebellomesencephalic fissure. METHODS: Nine formalin-fixed, latex-injected cadaveric head specimens were used to perform a midline SCIT and bilateral PCITs and measure the distance of each approach. Twenty-four formalin-fixed specimens were used to measure the distance from the most posterior cortical bridging vein entering the superior sagittal sinus to the calcarine sulcus and the torcula. Fifty-one magnetic resonance images were reviewed to calculate the angle of each approach. Three illustrative surgical cases were described. RESULTS: Mean distances from the brain or cerebellar surface to the operative target of the PCIT and SCIT were 7.1 cm (range: 5-7.7 cm) and 5.5 cm (range: 3.8-6.2 cm), respectively. The SCIT provided direct access to structures of the quadrigeminal cistern bilaterally. The PCIT provided access from the ipsilateral inferior colliculus to the ipsilateral infratrochlear zone. The PCIT's benefit was the direct access it provided to the cerebellomesencephalic fissure because of its superior to inferior trajectory. CONCLUSION: The PCIT is indicated for unilateral lesions of the cerebellomesencephalic fissure and dorsal brainstem that harbor a craniocaudal long axis and do not have a superior extension beyond the superior colliculi. The SCIT is beneficial for lesions that extend bilaterally, have an anteroposterior long axis, or involve the Galenic complex.
New-onset aortitis manifesting as relapsing giant cell arteritis successfully managed with tocilizumab monotherapy. A comment on: Optimisation of tocilizumab therapy in giant cell arteritis. by Calderon-Goercke et al.
Guarda, Max , Araoz, Philip A. , Ghaffar, Umar , Warrington, Kenneth J. , Koster, Matthew J.

Mayo Clinic

Clinical and Experimental Rheumatology | March 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/032qke | PMID 36995327 Get It

Tocilizumab for giant cell arteritis: what is optimal?
Kaymakci, Mahmut , Kaymakci, Mahmut S , Warrington, Kenneth J.

Mayo Clinic

Clinical and Experimental Rheumatology | March 27, 2023 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.55563/clinexprheumatol/u5tnbs | PMID 36995336 Get It

Diabetes and Vulvovaginal Conditions
O’Laughlin, Danielle , McCoy, Rozalina G. , O'Laughlin, Danielle J , McCoy, Rozalina Grubina

Mayo Clinic

Clinical Diabetes | March 27, 2023 | Volume: 41 | Issue: 3 | Pages: 458-464

10.2337/cd23-0011 | PMID 37456089 Get It

Brain Shrinkage in Anti–β-Amyloid Alzheimer Trials
Barkhof, Frederik , Barkhof, Frederik , Knopman, David S.

Mayo Clinic

Neurology | March 27, 2023 | Volume: 100 | Issue: 20 | Pages: 941-942

10.1212/wnl.0000000000207268 | PMID 36973045 Get It

Unpublished clinical trials of common rheumatic diseases
Pedersen, Connor , Tai, Shannon , Valley, Erin, Henry, Kathryn , Duarte‐García, Alí , Singla, Shikha , Putman, Michael , Duarte-García, Alí

Mayo Clinic

Rheumatology | March 27, 2023 | Volume: 62 | Issue: 12 | Pages: 3811-3818

10.1093/rheumatology/kead141 | PMID 36971599 Get It

Abstract Objectives Randomized controlled trials (RCTs) provide high-quality evidence for treatment efficacy, but many RCTs remain unpublished. The objective of this study was to describe the proportion of unpublished RCTs in five rheumatic diseases and to identify factors associated with publication. Methods Registered RCTs for five rheumatic diseases (SLE, vasculitis, spondyloarthritis, SS and PsA) with over 30 months since study completion were identified using ClinicalTrials.gov. Index publications were identified by NCT ID numbers and structured text searches of publication databases. The results of unpublished studies were identified in abstracts and press releases; reasons for non-publication were assessed by surveying corresponding authors. Results Out of 203 studies that met eligibility criteria, 17.2% remained unpublished, representing data from 4281 trial participants. Higher proportions of published trials were phase 3 RCTs (57.1% vs 28.6% unpublished, P &lt; 0.05) or had a positive primary outcome measure (64.9% vs 25.7% unpublished, P &lt; 0.001). In a multivariable Cox proportional hazards model, a positive outcome was independently associated with publication (hazard ratio 1.55; 95% CI: 1.09, 2.22). Corresponding authors of 10 unpublished trials cited ongoing preparation of the manuscript (50.0%), sponsor/funder issues (40.0%) and unimportant/negative result (20.0%) as reasons for lack of publication. Conclusions Nearly one in five RCTs in rheumatology remain unpublished 2 years after trial completion, and publication is associated with positive primary outcome measures. Efforts to encourage universal publication of rheumatology RCTs and reanalysis of previously unpublished trials should be undertaken.
Diagnostic error among vulnerable populations presenting to the emergency department with cardiovascular and cerebrovascular or neurological symptoms: a systematic review
Herasevich, Svetlana , Soleimani, Jalal , Huang, Chanyan , Pinevich, Yuliya , Pickering, Brian W. , Barwise, Amelia , Murad, Mohammad H, Barwise, Amelia K , Pinevich, Yuliya , Dong, Yue , Murad, M. Hassan

Mayo Clinic

BMJ Quality & Safety | March 27, 2023 | Volume: 32 | Issue: 11 | Pages: 676-688

10.1136/bmjqs-2022-015038 | PMID 36972982 Get It

Background Diagnostic error (DE) is a common problem in clinical practice, particularly in the emergency department (ED) setting. Among ED patients presenting with cardiovascular or cerebrovascular/neurological symptoms, a delay in diagnosis or failure to hospitalise may be most impactful in terms of adverse outcomes. Minorities and other vulnerable populations may be at higher risk of DE. We aimed to systematically review studies reporting the frequency and causes of DE in under-resourced patients presenting to the ED with cardiovascular or cerebrovascular/neurological symptoms. Methods We searched EBM Reviews, Embase, Medline, Scopus and Web of Science from 2000 through 14 August 2022. Data were abstracted by two independent reviewers using a standardised form. The risk of bias (ROB) was assessed using the Newcastle-Ottawa Scale, and the certainty of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation approach. Results Of the 7342 studies screened, we included 20 studies evaluating 7436,737 patients. Most studies were conducted in the USA, and one study was multicountry. 11 studies evaluated DE in patients with cerebrovascular/neurological symptoms, 8 studies with cardiovascular symptoms and 1 study examined both types of symptoms. 13 studies investigated missed diagnoses and 7 studies explored delayed diagnoses. There was significant clinical and methodological variability, including heterogeneity of DE definitions and predictor variable definitions as well as methods of DE assessment, study design and reporting. Among the studies evaluating cardiovascular symptoms, black race was significantly associated with higher odds of DE in 4/6 studies evaluating missed acute myocardial infarction (AMI)/acute coronary syndrome (ACS) diagnosis compared with white race (OR from 1.18 (1.12–1.24) to 4.5 (1.8–11.8)). The association between other analysed factors (ethnicity, insurance and limited English proficiency) and DE in this domain varied from study to study and was inconclusive. Among the studies evaluating DE in patients with cerebrovascular/neurological symptoms, no consistent association was found indicating higher or lower odds of DE. Although some studies showed significant differences, these were not consistently in the same direction. The overall ROB was low for most included studies; however, the certainty of evidence was very low, mostly due to serious inconsistency in definitions and measurement approaches across studies. Conclusions This systematic review demonstrated consistent increased odds of missed AMI/ACS diagnosis among black patients presenting to the ED compared with white patients in most studies. No consistent associations between demographic groups and DE related to cerebrovascular/neurological diagnoses were identified. More standardised approaches to study design, measurement of DE and outcomes assessment are needed to understand this problem among vulnerable populations. Trial registration number The study protocol was registered in the International Prospective Register of Systematic Reviews PROSPERO 2020 CRD42020178885 and is available from: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42020178885.
Hybrid Immunity Provides Protective Advantage Over Vaccination or Prior Remote Coronavirus Disease 2019 Alone
Virk, Abinash , Johnson, Matthew G. , Roellinger, Daniel , Scott, Christopher G. , Sampathkumar, Priya , Breeher, Laura E. , Swift, Melanie D. , Roellinger, Daniel L, Swift, Melanie D , Scott, Christopher , Breeher, Laura

Mayo Clinic

Open Forum Infectious Diseases | March 27, 2023 | Volume: 10 | Issue: 5 | Pages: No page available

10.1093/ofid/ofad161 | PMID 37180597 Get It

Abstract Background The protective efficacy of prior coronavirus disease 2019 (COVID-19) with or without vaccination remains unknown. This study sought to understand if 2 or more messenger RNA (mRNA) vaccine doses provide additional protection in patients with prior infection, or if infection alone provides comparable protection. Methods We conducted a retrospective cohort study of the risk of COVID-19 from 16 December 2020 through 15 March 2022, among vaccinated and unvaccinated patients of all ages with and without prior infection. A Simon-Makuch hazard plot illustrated the incidence of COVID-19 between groups. Multivariable Cox proportional hazards regression was used to examine the association of demographics, prior infection, and vaccination status with new infection. Results Among 101 941 individuals with at least 1 COVID-19 polymerase chain reaction test prior to 15 March 2022, 72 361 (71.0%) received mRNA vaccination and 5957 (5.8%) were previously infected. The cumulative incidence of COVID-19 was substantially higher throughout the study period for those previously uninfected and unvaccinated, and lowest for those previously infected and vaccinated. After accounting for age, sex, and the interaction between vaccination and prior infection, a reduction in reinfection risk was noted during the Omicron and pre-Omicron phases of 26% (95% confidence interval [CI], 8%–41%; P = .0065) to 36% (95% CI, 10%–54%; P = .0108), respectively, among previously infected and vaccinated individuals, compared to previously infected subjects without vaccination. Conclusions Vaccination was associated with lower risk of COVID-19, including in those with prior infection. Vaccination should be encouraged for all including those with prior infection, especially as new variants emerge and variant-specific booster vaccines become available.